Manufacturers lobby against patent waivers; Moderna effective in children 12-17: Latest COVID-19 vaccine news

Here are eight new developments about the COVID-19 vaccine from the last week:

  1. Manufacturers of the COVID-19 vaccine are dedicating more effort to lobby against patent waivers, citing production concerns and worries that waivers will not address shortages.
  2. Half of adults in the U.S. are now fully vaccinated against COVID-19 and 39.5 percent of the entire U.S. population is fully vaccinated, according to the CDC.
  3. Pfizer recently began a trial to test the effects of adults aged 65 and older who are fully vaccinated receiving a pneumococcal conjugate vaccine and a third dose of Pfizer's COVID-19 vaccine.
  4. Moderna announced that its COVID-19 vaccine is 100 percent effective in preventing symptomatic COVID-19 in children ages 12-17 years old.
  5. Vaccine manufacturers have begun developing vaccines aimed at fighting against coronavirus variants, The Atlantic reported.
  6. Pfizer-BioNTech's and AstraZeneca's COVID-19 vaccines have been found to be effective against the more transmissible variant first found in India for people who are fully vaccinated.
  7. The CDC is investigating cases of mostly teenagers and young adults who experienced myocarditis after being vaccinated.
  8. The CDC recently issued new guidance stating that healthcare providers giving vaccines should prioritize vaccinating as many people as possible over ensuring doses don't go to waste.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast